Point72 Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Point72 Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Buy	+77,658	New	+$1.29M	﹤0.01%	2694
2025 Q1	–	Sell	-26,600	Closed	-$352K	–	2520
2024 Q4	$352K	Buy	+26,600	New	+$365K	﹤0.01%	1751
2024 Q2	–	Sell	-206,100	Closed	-$2.86M	–	2427
2024 Q1	$2.86M	Buy	+206,100	New	+$3M	0.01%	1150
2023 Q3	–	Sell	-2,125,500	Closed	-$33.4M	–	2859
2023 Q2	$33.4M	Sell	2,125,500 -403,297	-16%	-$6.61M	0.1%	258
2023 Q1	$41.7M	Sell	2,528,797 -253,903	-9%	-$4.04M	0.13%	197
2022 Q4	$43.4M	Buy	+2,782,700	New	+$38.9M	0.15%	185
2021 Q4	–	Sell	-1,299,900	Closed	-$21.3M	–	1295
2021 Q3	$21.3M	Sell	1,299,900 -77,100	-6%	-$1.29M	0.09%	289
2021 Q2	$23.2M	Buy	+1,377,000	New	+$23.4M	0.1%	252
2021 Q1	–	Sell	-651,300	Closed	-$11.9M	–	1174
2020 Q4	$11.9M	Buy	+651,300	New	+$11.4M	0.06%	403
2019 Q4	–	Sell	-267,562	Closed	-$4.6M	–	1239
2019 Q3	$4.6M	Buy	+267,562	New	+$4.63M	0.03%	472
2019 Q2	–	Sell	-976,514	Closed	-$19.9M	–	1522
2019 Q1	$19.9M	Buy	+976,514	New	+$19.7M	0.09%	255

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Point72 Asset Management's TAK Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Takeda Pharmaceutical (TAK) in Q2 2026: 77,658 shares worth $1.24M. The stake represents ﹤0.01% of the portfolio and ranks #2694 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in TAK as recently as Q4 2024.

Point72 Asset Management first reported a position in TAK in Q1 2019 and has held it in 11 quarters since. The position peaked at $43.4M in Q4 2022. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Point72 Asset Management held 77,658 shares of Takeda Pharmaceutical worth $1.24M as of Q2 2026.
Takeda Pharmaceutical was a new Point72 Asset Management position in Q2 2026.
Takeda Pharmaceutical made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #2694 holding.
Point72 Asset Management first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 11 quarters since.
Point72 Asset Management's Takeda Pharmaceutical position peaked at $43.4M in Q4 2022.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.